<DOC>
	<DOC>NCT00858572</DOC>
	<brief_summary>The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.</brief_summary>
	<brief_title>STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders</brief_title>
	<detailed_description />
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Inclusion Criteria Males and females 18 years or older Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol Must have acceptable organ function during screening as defined in the protocol Exclusion Criteria Pregnant or breastfeeding women Patients must meet the washout periods for prior chemotherapies and radiation History of stroke within 6 months of treatment Poor venous access for study drug administration Treatment with chronic immunosuppressants Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Synta</keyword>
	<keyword>STA-9090</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
	<keyword>myeloproliferative disorder</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>ganetespib</keyword>
</DOC>